RXST Earnings Prediction
The chart below shows how RXST performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RXST sees a -4.83% change in stock price 10 days leading up to the earnings, and a +4.96% change 10 days following the report. On the earnings day itself, the stock moves by +0.80%. This data can give you a slight idea of what to expect for the next quarter's release.
RXST Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
40.21M
40.71%
13.88%
Gross Margin
71.59%
15.90%
0.24%
Operating Margin
-21.46%
-43.48%
-17.87%
Net Margin
-14.77%
-54.00%
-17.72%
EPS
-0.15
-42.31%
-6.25%
No Data Available
RXST Earnings Analysis
Rxsight Inc Corporation (RXST.O) Earnings Conference Call
Positive
Fourth Quarter Revenue Surge: Consistent with our January preannouncement RxSight reported fourth quarter 2024 revenue of $40.2 million, up 41% compared to the year ago quarter.
Broad-Based Growth Drivers: Growth was broad based, driven by strong growth in LAL procedure volume and the continued expansion of our installed base of LDDS.
Record LAL Sales Growth: We sold a record of 29,069 LALs in the period, up 61% from the fourth quarter of 2023.
LAL Revenue Surge: These procedure volumes translated into LAL revenue of $28.5 million in the fourth quarter of 2024, up 60% compared to the year ago quarter.
Installed Base Growth: We ended 2024 with an LDD installed base of 971 units, up 46% compared to the 666 units installed at the end of 2023.
LAL Revenue Mix Increase: Higher LAL volume in the fourth quarter also led to an increased LAL revenue mix, with LAL revenue accounting for 71% of total revenue, up from 62% in the fourth quarter of 2023.
Gross Margin Expansion: This shift in mix, combined with LDD sales with a lower manufacturing cost and higher average selling price expanded our gross margin to 71.6% in the fourth quarter of 2024, up from 61.8% in the fourth quarter of 2023.
Revenue Surge Analysis: During the year, revenue grew 57% to $139.9 million, driven by a 78% increase in LAL revenue and a 24% increase in LDD revenue.
Gross Profit Margin Increase: Our full year 2024 gross profit margin was 70.7% compared to 60.4% in 2023.
Strong Cash Position: We ended the year with no debt and $237.2 million in cash, cash equivalents and short-term investments.
2025 Revenue Guidance Reaffirmed: We are reaffirming the guidance we provided in January as we continue to expect 2025 full year revenue to range between $185 million to $197 million representing year-over-year growth of 32% to 41%.
Gross Margin Expectations: We expect our full year 2025 gross margin to be in the range of 71% to 73%, reflecting a continued increase in revenue mix from the higher margin LAL procedure volume.
Market Share Expansion: Since RxSight went public and began scaling its U.S. commercial team in Q3 2021, the new adjustable premium IOL category we created has grown to approximately 10% of the overall U.S. premium IOL market on a procedure volume basis through Q4 2024.
Adjustable Premium IOL Growth: In 2024 we believe that adjustable premium IOLs accounted for nearly half of the overall growth of premium IOLs in the U.S.
Premium Revenue Increase: Practices that adopted our technology are estimated to have increased overall U.S. practice level premium revenue by approximately 10%.
Cataract Surgeon Technology Adoption: With about 1,500 of the approximately 10,000 U.S. cataract surgeons trained on our technology, we anticipate a long runway for continued LDD placements in offices serving cataract patients.
FDA Approval for New Functionality: We received FDA approval for an additional LDD functionality that builds on our clinical experience with aspheric optics, scheduled for release in the second half of 2025.
Negative
Rising SG&A Expenses: Fourth quarter 2024 SG&A expenses increased by 33% year-over-year to $28.2 million, indicating rising operational costs that could impact profitability.
R&D Expense Increase: Research and development expenses rose by 25% year-over-year to $9.2 million, reflecting increased facility costs and salaries, which may strain financial resources.
Net Loss Amid Revenue Growth: Despite revenue growth, the company reported a net loss of $5.9 million in Q4 2024, highlighting ongoing financial challenges and the need for improved profitability.
Operating Expenses Surge: Total operating expenses for 2024 were $135.8 million, a 31% increase compared to 2023, suggesting that rising costs are outpacing revenue growth.
Operating Expense Increase Forecast: The company expects operating expenses in 2025 to increase by 22% to 25%, which could further pressure margins and profitability in the coming year.
Limited International Growth Potential: Revenue contribution outside of North America is expected to remain nominal in 2025, indicating limited growth potential in international markets for the near term.
RXST FAQs
How does RXST typically perform around its earnings report dates?
Is Rxsight Inc (RXST) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
RXST Earning Call Sentiment
RxSight, Inc. (RXST) Q4 2024 Earnings Call Transcript
RXST.O
3.57%Positive
The earnings call reveals strong financial performance, with significant revenue and margin growth, and improved net loss figures. Despite increased expenses, the company maintains a healthy cash position with no debt. The Q&A session highlights confidence in continued growth and market adoption, although some responses lack specificity. The absence of a shareholder return plan is a minor negative, but overall, the strong financial metrics and optimistic guidance suggest a positive stock price movement, especially given the company's small-cap status.
